In 2018, FDA issued a final guidance to the industry on DMD drug development.9 The guidance notes that “FDA has no defined set of required or recommended clinical outcome measures for studies in dystrophinopathies...” and suggests that existing or novel outcome measures that can measure clinically meaningful effects may be appropriate. The gene discussed is DMD; the disease is neuromuscular disease caused by qualitative or quantitative defects of dystrophin.